接受纳武利尤单抗治疗的晚期黑色素瘤患者的生存、持久肿瘤缓解与长期安全性
这项研究纳入2008至2012年间107例晚期黑色素瘤患者,接受纳武利尤单抗静脉给药每2周一次最长96周。中位总生存期为16.8个月,1年和2年生存率分别为62%和43%;33例客观缓解患者的中位缓解持续时间估计为2年,17例因非疾病进展停药者中12例(71%)在停药后维持缓解至少16周。长期安全性可接受。
要点
- 107例晚期黑色素瘤患者接受纳武利尤单抗,中位总生存期16.8个月,1年生存率62%、2年生存率43%。
- 33例(31%)达客观缓解,中位缓解持续时间估计为2年。
- 17例因非疾病进展停药者中12例(71%)停药后维持缓解至少16周。
核心结论
- 晚期难治性黑色素瘤患者接受纳武利尤单抗后的总生存期与类似患者群体的文献研究相比具有优势。
- 缓解持久且在停药后仍持续。
- 长期安全性可接受。
- 正在进行的随机临床试验将进一步评估纳武利尤单抗对转移性黑色素瘤患者总生存期的影响。
研究设计与样本
- 患者为2008年至2012年间入组的晚期黑色素瘤患者(N=107)。
- 在门诊接受纳武利尤单抗静脉给药,每2周一次,最长96周。
- 观察总生存期、长期安全性及停药后缓解持续时间。
主要发现
- 纳武利尤单抗治疗患者的中位总生存期为16.8个月,其中62%既往接受过2至5种全身治疗。
- 1年生存率为62%,2年生存率为43%。
- 33例(31%)达客观肿瘤缓解,Kaplan-Meier估计的中位缓解持续时间为2年。
- 17例因疾病进展以外的原因停药,其中12例(71%)在停药后维持缓解至少16周(范围16至56+周)。
- 客观缓解率和毒性率与既往报道相似;对全部306例接受该试验治疗患者(包括其他癌症类型)的扩展分析中,经暴露校正的毒性率未呈累积性。
局限性
- 未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued. PATIENTS AND METHODS: Patients with advanced melanoma (N = 107) enrolled between 2008 and 2012 received intravenous nivolumab in an outpatient setting every 2 weeks for up to 96 weeks and were observed for overall survival, long-term safety, and response duration after treatment discontinuation. RESULTS: Median overall survival in nivolumab-treated patients (62% with two to five prior systemic therapies) was 16.8 months, and 1- and 2-year survival rates were 62% and 43%, respectively. Among 33 patients with objective tumor regressions (31%), the Kaplan-Meier estimated median response duration was 2 years. Seventeen patients discontinued therapy for reasons other than disease progression, and 12 (71%) of 17 maintained responses off-therapy for at least 16 weeks (range, 16 to 56+ weeks). Objective response and toxicity rates were similar to those reported previously; in an extended analysis of all 306 patients treated on this trial (including those with other cancer types), exposure-adjusted toxicity rates were not cumulative. CONCLUSION: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations. Responses were durable and persisted after drug discontinuation. Long-term safety was acceptable. Ongoing randomized clinical trials will further assess the impact of nivolumab therapy on overall survival in patients with metastatic melanoma.
引用
- Topalian SL, Sznol M, McDermott DF, et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol. 2023. PMID: 36750016. doi:10.1200/JCO.22.02272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。